Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

[1]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[3]  A. Ivanova,et al.  A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. , 2017, The Lancet. Oncology.

[4]  A. Talhouk,et al.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. , 2016, Gynecologic oncology.

[5]  K. K. van de Vijver,et al.  L1CAM expression in endometrial carcinomas: an ENITEC collaboration study , 2016, British Journal of Cancer.

[6]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[7]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[8]  H. Putter,et al.  Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. , 2015, International journal of radiation oncology, biology, physics.

[9]  T. Bosse,et al.  Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.

[10]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[11]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[12]  T. Bosse,et al.  L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.

[13]  A. Stiggelbout,et al.  Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians , 2014, British Journal of Cancer.

[14]  T. Bosse,et al.  High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. , 2014, Gynecologic oncology.

[15]  P. Altevogt,et al.  L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.

[16]  K. Bertelsen,et al.  Omitting Adjuvant Radiotherapy in Endometrial Cancer Increases the Rate of Locoregional Recurrences but Has no Effect on Long-Term Survival: The Danish Endometrial Cancer Study , 2013, International Journal of Gynecologic Cancer.

[17]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[18]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[19]  G. Thomas.  A Role for Adjuvant Radiation in Clinically Early Carcinoma of the Endometrium? , 2010, International Journal of Gynecologic Cancer.

[20]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[21]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[22]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[23]  S. Ziebland,et al.  Is ‘watchful waiting’ a real choice for men with prostate cancer? A qualitative study , 2002, BJU international.

[24]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[25]  C. Charles,et al.  Doing Nothing is No Choice: Lay Constructions of Treatment Decision‐making Among Women with Early‐stage Breast Cancer , 1998 .